Skip to Main Content

A Single-arm Phase II Trial to Evaluate the Safety and Efficacy of the Antibody-Drug Conjugate (ADC) SYD985 in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Endometrial Carcinoma Who Previously Progressed on or After First Line Platinum-based Chemotherapy

Conditions

Corpus Uteri

Phase II

What is the purpose of this trial?

The purpose of this study is to evaluate the safety and efficacy of SYD985 in recurrent, advanced or metastatic endometrial cancer.

  • Ages
    18 years and older
  • Gender
    Female only
  • Trial with
    Synthon Biopharmaceuticals BV
  • Start Date
    07/05/2020
  • End Date
    03/31/2022

For more information about this study, contact:

Lisa Baker

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/07/2020
  • Study HIC
    #2000026973